Valuation : Intra-Cellular Therapies, Inc.

Market Cap 14.02B 12.11B 11.35B 10.36B 19.49B 1,337B 19.59B 134B 52.51B 676B 52.64B 51.49B 2,244B P/E 2023
-49.2x
P/E 2024 -115x
Enterprise Value 13.04B 11.26B 10.55B 9.63B 18.12B 1,244B 18.21B 125B 48.82B 629B 48.94B 47.88B 2,086B EV / Sales 2023
13.8x
EV / Sales 2024 11.6x
Free-Float
95.68%
Yield 2023 *
-
Yield 2024 -
3 years 45.5
Extreme 45.5
131.98
5 years 31.42
Extreme 31.42
131.98
10 years 6.75
Extreme 6.75
131.98
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 31/03/2022
Compliance Officer 64 01/07/2019
Corporate Secretary - -
Date Insider Type Main position Quantity % Market Cap.
02/04/25 Issuer saleCompany 10,000 0.0094%
02/04/25 Issuer sale

Director

55,511 0.0522%
02/04/25 Issuer sale

Chief Technology Officer

265,944 0.2501%
Change 5-day change 1-year change 3-year change Capi.($)
-0.04%-.--%-.--%+138.51% 14.02B
-1.67%-4.78%+37.02%-4.42% 79.3B
-0.90%+2.39%-18.98%-35.69% 59.21B
-3.35%-4.92%+463.91%+21.22% 55.09B
-6.78%-4.19%-4.50%+28.86% 49.86B
-2.43%-2.35%+8.03%+163.45% 47.9B
-1.35%+0.79%+64.72%-17.56% 32.28B
-2.64%-2.69%+48.59%+91.84% 25.21B
-0.09%+4.98%+18.59%+209.35% 23.87B
-0.34%+1.35%+60.10%+122.64% 16.89B
Average -1.96%-1.08%+67.75%+71.82% 40.36B
Weighted average by Cap. -2.34%-1.98%+80.03%+46.41%

Financials

2023 2024
Net sales 464M 401M 376M 343M 646M 44.29B 649M 4.45B 1.74B 22.4B 1.74B 1.71B 74.32B 681M 588M 551M 503M 946M 64.94B 951M 6.53B 2.55B 32.84B 2.56B 2.5B 109B
Net income -140M -121M -113M -103M -194M -13.32B -195M -1.34B -523M -6.74B -524M -513M -22.35B -74.68M -64.47M -60.44M -55.18M -104M -7.12B -104M -716M -280M -3.6B -280M -274M -11.95B
Net Debt -481M -415M -389M -355M -669M -45.88B -672M -4.61B -1.8B -23.2B -1.81B -1.77B -76.98B -984M -850M -796M -727M -1.37B -93.86B -1.37B -9.44B -3.69B -47.46B -3.69B -3.61B -157B
Logo Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on the development and commercialization of small molecule drugs that address underserved medical needs primarily in psychiatric and neurological disorders. The Company’s product, CAPLYTA (lumateperone), is an oral, once daily atypical antipsychotic approved in adults for the treatment of schizophrenia and the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. Lumateperone is also being studied for the treatment of major depressive disorder, and other psychiatric and neurological disorders. Its pipeline includes several product candidates in clinical development and additional product candidates in non-clinical testing, such as the ITI-1284-ODT-SL program, Phosphodiesterase type I inhibitor (PDE1) program, ITI-333 program, and ITI-1500 Non-Hallucinogenic Psychedelic program.
Employees
860
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. ITCI Stock